Two rivaroxaban regimens combined with either a P2Y12 inhibitor or dual antiplatelet therapy (DAPT) reduced bleeding vs a combination of vitamin K antagonist (warfarin) and DAPT in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) with stenting, the PIONEER AF-PCI* has shown.
The addition of evolocumab to statin therapy in individuals with angiographic coronary disease appeared to encourage coronary atherosclerosis regression, as demonstrated in the GLAGOV* trial presented at the Scientific Sessions of the American Heart Association (AHA 2016) held in New Orleans, Louisiana, US.
Moderate doses of celecoxib are noninferior to naproxen or ibuprofen in terms of cardiovascular (CV) safety, according to results of the PRECISION* trial presented at the Scientific Sessions of the American Heart Association held recently in New Orleans, Louisiana, US.
Intravenous ferric carboxymaltose appears to produce a significant improvement in exercise capacity, as measured by peak oxygen consumption (VO2), in symptomatic patients with heart failure (HF) and iron deficiency, according to the results of the EFFECT-HF trial presented at the American Heart Association (AHA) 2016 Scientific Sessions.
Ticagrelor is not superior to clopidogrel in reducing cardiovascular events in patients with symptomatic peripheral artery disease (PAD), according to primary results of the EUCLID* trial presented at the Scientific Sessions of the American Heart Association held recently in New Orleans, Louisiana, US.
Post-percutaneous coronary intervention (PCI) patients with the loss-of-function variant of the CYP2C19 gene are at a higher risk of major adverse cardiac events (MACE) if they were prescribed clopidogrel instead of alternative anti-platelet therapies, according to a study presented at the American Heart Association Scientific Sessions 2016.
A heart failure monitoring solution that features a multi-sensor algorithm has shown compelling performance in detecting impending heart failure events (HFEs) in patients with implanted devices, providing a timely alert and thereby an opportunity for interventional treatment, according to the results of the MultiSENSE study presented at the American Heart Association (AHA) 2016 Scientific Sessions.
Allogeneic mesenchymal stem cell therapy presented high safety, tolerability and efficacy in non-ischaemic dilated cardiomyopathy patients, according to the results of the POSEIDON-DCM trial presented at the American Heart Association Scientific Sessions 2016.
Blood pressure lowering medications and statins do not prevent cognitive and functional decline in elderly patients, according to results of the HOPE-3 trial* presented at the Scientific Sessions of the American Heart Association (AHA 2016) held recently in New Orleans, Louisiana, US.
Infusions of recombinant apolipoprotein A-1 (apoA-1) Milano, a high-density lipoprotein (HDL) mimetic containing apoA-1, did not produce significant regression of coronary atherosclerosis in acute coronary syndrome (ACS) patients as assessed by intravascular ultrasound (IVUS) despite promising data from previous trials, according to final data from the MILANO-PILOT* trial presented at the American Heart Association 2016 Scientific Sessions (AHA 2016) held recently in New Orleans, Louisiana, US.
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.